Literature DB >> 12096211

Evolving concepts on the value of adenosine hyperresponsiveness in asthma and chronic obstructive pulmonary disease.

R Polosa1, S Rorke, S T Holgate.   

Abstract

Adenosine is a purine nucleoside which mediates a variety of cellular responses relevant to asthma and COPD through interaction with specific receptors. Administration of adenosine by inhalation to patients with asthma and COPD is known to cause concentration related bronchoconstriction. Responses elicited by this purine derivative in asthma and COPD should not be considered as a mere reflection of non-specific airways hyperresponsiveness. Evaluation of airways responsiveness by adenosine induced bronchoconstriction may be valuable in differentiating asthma from COPD, monitoring of anti-inflammatory treatment in asthma, surveying disease progression, and assessing disease activity in relation to allergic airways inflammation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12096211      PMCID: PMC1746364          DOI: 10.1136/thorax.57.7.649

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  79 in total

1.  Effect of allergen avoidance at high altitude on direct and indirect bronchial hyperresponsiveness and markers of inflammation in children with allergic asthma.

Authors:  E van Velzen; J W van den Bos; J A Benckhuijsen; T van Essel; R de Bruijn; R Aalbers
Journal:  Thorax       Date:  1996-06       Impact factor: 9.139

Review 2.  Role of mast cells and basophils in asthma.

Authors:  A E Redington; R Polosa; A F Walls; P H Howarth; S T Holgate
Journal:  Chem Immunol       Date:  1995

3.  Differences in the effect of allergen avoidance on bronchial hyperresponsiveness as measured by methacholine, adenosine 5'-monophosphate, and exercise in asthmatic children.

Authors:  J Benckhuijsen; J W van den Bos; E van Velzen; R de Bruijn; R Aalbers
Journal:  Pediatr Pulmonol       Date:  1996-09

4.  Is there a specific phenotype for asthma?

Authors:  A J Woolcock; G King
Journal:  Clin Exp Allergy       Date:  1995-11       Impact factor: 5.018

Review 5.  Nomenclature and classification of purinoceptors.

Authors:  B B Fredholm; M P Abbracchio; G Burnstock; J W Daly; T K Harden; K A Jacobson; P Leff; M Williams
Journal:  Pharmacol Rev       Date:  1994-06       Impact factor: 25.468

Review 6.  Cloned adenosine A3 receptors: pharmacological properties, species differences and receptor functions.

Authors:  J Linden
Journal:  Trends Pharmacol Sci       Date:  1994-08       Impact factor: 14.819

7.  Adenosine, methacholine, and exercise challenges in children with asthma or paediatric chronic obstructive pulmonary disease.

Authors:  A Avital; C Springer; E Bar-Yishay; S Godfrey
Journal:  Thorax       Date:  1995-05       Impact factor: 9.139

8.  Inhaled lysine acetylsalicylate (L-ASA) attenuates the bronchoconstrictor response to adenosine 5'-monophosphate (AMP) in asthmatic subjects.

Authors:  N Crimi; R Polosa; S Magrì; G Prosperini; V L Milazzo; G Santonocito; A Mistretta
Journal:  Eur Respir J       Date:  1995-06       Impact factor: 16.671

9.  Release of mast-cell-derived mediators after endobronchial adenosine challenge in asthma.

Authors:  R Polosa; W H Ng; N Crimi; C Vancheri; S T Holgate; M K Church; A Mistretta
Journal:  Am J Respir Crit Care Med       Date:  1995-03       Impact factor: 21.405

10.  Adenosine A2b receptors evoke interleukin-8 secretion in human mast cells. An enprofylline-sensitive mechanism with implications for asthma.

Authors:  I Feoktistov; I Biaggioni
Journal:  J Clin Invest       Date:  1995-10       Impact factor: 14.808

View more
  13 in total

1.  Regadenoson stress in patients with asthma and COPD: a breath of fresh air.

Authors:  Randall C Thompson
Journal:  J Nucl Cardiol       Date:  2012-08       Impact factor: 5.952

2.  Stimulatory effect of CO2 on vagal bronchopulmonary C-fiber afferents during airway inflammation.

Authors:  Ruei-Lung Lin; Qihai Gu; You-Shuei Lin; Lu-Yuan Lee
Journal:  J Appl Physiol (1985)       Date:  2005-06-30

3.  The Quintiles Prize Lecture 2004. The identification of the adenosine A2B receptor as a novel therapeutic target in asthma.

Authors:  Stephen T Holgate
Journal:  Br J Pharmacol       Date:  2005-08       Impact factor: 8.739

4.  Mast cell involvement in the adenosine mediated airway hyper-reactivity in a murine model of ovalbumin-induced lung inflammation.

Authors:  Daniel Wyss; Olivier Bonneau; Alexandre Trifilieff
Journal:  Br J Pharmacol       Date:  2005-08       Impact factor: 8.739

5.  Adenosine A(1) and prostaglandin E receptor 3 receptors mediate global airway contraction after local epithelial injury.

Authors:  Jian Zhou; Martha B Alvarez-Elizondo; Elliot Botvinick; Steven C George
Journal:  Am J Respir Cell Mol Biol       Date:  2012-12-06       Impact factor: 6.914

Review 6.  Inhaled corticosteroids in the long-term management of patients with chronic obstructive pulmonary disease.

Authors:  Don D Sin; S F Paul Man
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

7.  Leukotriene C4 synthase polymorphisms and responsiveness to leukotriene antagonists in asthma.

Authors:  Graeme P Currie; John J Lima; Jim E Sylvester; Daniel K C Lee; Wendy J R Cockburn; Brian J Lipworth
Journal:  Br J Clin Pharmacol       Date:  2003-10       Impact factor: 4.335

8.  Effects of fluticasone plus salmeterol versus twice the dose of fluticasone in asthmatic patients.

Authors:  Graeme P Currie; Caroline E Bates; Daniel K C Lee; Catherine M Jackson; Brian J Lipworth
Journal:  Eur J Clin Pharmacol       Date:  2003-03-22       Impact factor: 2.953

9.  The Effect of Adenosine A2A and A2B Antagonists on Tracheal Responsiveness, Serum Levels of Cytokines and Lung Inflammation in Guinea Pig Model of Asthma.

Authors:  Laleh Pejman; Hasan Omrani; Zahra Mirzamohammadi; Amir Ali Shahbazfar; Majid Khalili; Rana Keyhanmanesh
Journal:  Adv Pharm Bull       Date:  2013-12-24

10.  A proof of concept study to evaluate putative benefits of montelukast in moderate persistent asthmatics.

Authors:  Graeme P Currie; Daniel K C Lee; Owen J Dempsey; Stephen J Fowler; Louise M Cowan; Brian J Lipworth
Journal:  Br J Clin Pharmacol       Date:  2003-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.